Table 4.
Plasmid name |
Vector backbone |
Antibiotic resistance |
Vector fragment (kpb) |
Insert size (kpb) |
RE to excise fragment |
---|---|---|---|---|---|
A |
PCR‐XL‐TOPO (Invitrogen) |
Kanamycin 30 µg/ml |
3.5 |
4.9 |
MluI × BsmBI |
B |
pSMART‐LC (Lucigen) |
Ampicillin 50 µg/ml |
1.2 + 0.8 |
4.7 |
BglI × BsmBI |
C |
pSMART‐LC (Lucigen) |
Ampicillin 50 µg/ml |
1.2 + 1.5 |
2.0 |
BglI × BsmBI |
D |
pSMART‐LC (Lucigen) |
Ampicillin 50 µg/ml |
1.0 + 1.0 |
1.45 |
AhdI × BsmBI |
E |
pSMART‐LC (Lucigen) |
Ampicillin 50 µg/ml |
1.2 + 0.8 |
2.8 |
BglI × BsmBI |
F |
PCR‐XL‐TOPO (Invitrogen) |
Kanamycin 30 µg/ml |
3.5 |
7.0 |
BsmBI |
G |
pBR322 |
Ampicillin 50 µg/ml |
2.2 + 2.1 |
8.7 |
SfiI × BsmBI |
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.